PHIO
Price
$2.19
Change
+$0.14 (+6.86%)
Updated
Apr 24, 02:43 PM (EDT)
Capitalization
11.99M
SAGE
Price
$7.59
Change
-$0.03 (-0.39%)
Updated
Apr 24, 02:34 PM (EDT)
Capitalization
468.48M
5 days until earnings call
Ad is loading...

PHIO vs SAGE

Header iconPHIO vs SAGE Comparison
Open Charts PHIO vs SAGEBanner chart's image
Phio Pharmaceuticals
Price$2.19
Change+$0.14 (+6.86%)
Volume$173
Capitalization11.99M
Sage Therapeutics
Price$7.59
Change-$0.03 (-0.39%)
Volume$100
Capitalization468.48M
PHIO vs SAGE Comparison Chart
Loading...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHIO vs. SAGE commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHIO is a Buy and SAGE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (PHIO: $2.05 vs. SAGE: $7.62)
Brand notoriety: PHIO and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHIO: 25% vs. SAGE: 76%
Market capitalization -- PHIO: $11.99M vs. SAGE: $468.48M
PHIO [@Biotechnology] is valued at $11.99M. SAGE’s [@Biotechnology] market capitalization is $468.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHIO’s FA Score shows that 0 FA rating(s) are green whileSAGE’s FA Score has 0 green FA rating(s).

  • PHIO’s FA Score: 0 green, 5 red.
  • SAGE’s FA Score: 0 green, 5 red.
According to our system of comparison, PHIO is a better buy in the long-term than SAGE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHIO’s TA Score shows that 5 TA indicator(s) are bullish while SAGE’s TA Score has 7 bullish TA indicator(s).

  • PHIO’s TA Score: 5 bullish, 5 bearish.
  • SAGE’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, SAGE is a better buy in the short-term than PHIO.

Price Growth

PHIO (@Biotechnology) experienced а -24.07% price change this week, while SAGE (@Biotechnology) price change was +3.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

PHIO is expected to report earnings on Mar 31, 2025.

SAGE is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAGE($468M) has a higher market cap than PHIO($12M). SAGE YTD gains are higher at: 40.331 vs. PHIO (13.889). PHIO has higher annual earnings (EBITDA): -7.41M vs. SAGE (-409.48M). SAGE has more cash in the bank: 504M vs. PHIO (5.39M). PHIO has less debt than SAGE: PHIO (0) vs SAGE (11.8M). SAGE has higher revenues than PHIO: SAGE (41.2M) vs PHIO (0).
PHIOSAGEPHIO / SAGE
Capitalization12M468M3%
EBITDA-7.41M-409.48M2%
Gain YTD13.88940.33134%
P/E Ratio0.01N/A-
Revenue041.2M-
Total Cash5.39M504M1%
Total Debt011.8M-
FUNDAMENTALS RATINGS
PHIO vs SAGE: Fundamental Ratings
PHIO
SAGE
OUTLOOK RATING
1..100
4014
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
3758
P/E GROWTH RATING
1..100
5696
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAGE's Valuation (35) in the Pharmaceuticals Other industry is in the same range as PHIO (66) in the Biotechnology industry. This means that SAGE’s stock grew similarly to PHIO’s over the last 12 months.

SAGE's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as PHIO (100) in the Biotechnology industry. This means that SAGE’s stock grew similarly to PHIO’s over the last 12 months.

SAGE's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as PHIO (96) in the Biotechnology industry. This means that SAGE’s stock grew similarly to PHIO’s over the last 12 months.

PHIO's Price Growth Rating (37) in the Biotechnology industry is in the same range as SAGE (58) in the Pharmaceuticals Other industry. This means that PHIO’s stock grew similarly to SAGE’s over the last 12 months.

PHIO's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for SAGE (96) in the Pharmaceuticals Other industry. This means that PHIO’s stock grew somewhat faster than SAGE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PHIOSAGE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 17 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
67%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAMVX93.74N/A
N/A
FAM Value Investor
AREDX25.72N/A
N/A
American Century Real Estate R6
ICTVX10.05N/A
N/A
ICON Utilities and Income Inv
SREQX12.50N/A
N/A
PGIM Select Real Estate R6
TQAIX38.11N/A
N/A
T. Rowe Price Integrated US Sm Gr Eq I

PHIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHIO has been loosely correlated with MTNB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PHIO jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHIO
1D Price
Change %
PHIO100%
-18.33%
MTNB - PHIO
50%
Loosely correlated
-2.48%
TPST - PHIO
49%
Loosely correlated
+4.09%
BPMC - PHIO
40%
Loosely correlated
+2.81%
IMNN - PHIO
39%
Loosely correlated
-1.34%
SAGE - PHIO
38%
Loosely correlated
-0.78%
More